🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Oramed Pharmaceuticals Inc. ORMP PHARMA

Healthcare · Biotechnology · United States
https://oramed.com
Company Profile ↓
$4.98
+151.97% 1Y
Mkt Cap$203.81M
P/E1.21
P/B0.62
Div. Yield5.36%
52W High$5.34
52W Low$1.92
Book Value$7.68
EPS (TTM)$4.13

Company Overview

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 74.2%, reflecting efficient use of shareholder capital.

Steady Revenue Expansion

Revenue has grown at a 13.5% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 1.2, below the sector median of 24.8.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.23.

Dividend Income

Offers a dividend yield of 5.36%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Trailing 12 Months Year-on-year growth — earnings +493.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 13.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:13.48%
1 Year:-

Compounded Profit Growth

5 Years:-
1 Year:493.50%

Stock Price Performance

1 Year:+151.97%
6 Months:+52.76%
3 Months:+36.81%
1 Month:+15.81%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 89% of range
$1.92 $5.34
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)58.35 · Neutral
Price Performance
1M+15.81%
3M+36.81%
6M+52.76%
1Y+151.97%
Valuation vs Sector

P/E of 1.21 is below the sector median of 24.83 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 74.2%.
  • Compounding revenue at 13.5% over 5 years.
  • Attractive dividend yield of 5.36%.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
1.21
Industry PE
24.83
Forward P/E
-62.25
PEG Ratio
-
Book Value
$7.68
Price to Book
0.62
P/S
inf
EV/EBITDA
-10.23
Dividend Yield
5.36%

Growth (CAGR)

Revenue 5Y
13.48%
Profit 5Y
-
Revenue (YoY)
-
Earnings (YoY)
493.50%

Profitability & Returns

ROCE
-7.12%
ROE
74.24%
ROA
-3.42%
Profit Margin
0.00%
Op Margin
0.00%
Gross Margin
0.00%
EPS (Latest Qtr)
$1.84
EPS (TTM)
$4.13

Balance Sheet & Liquidity

Debt/Equity
0.23
Quick Ratio
4.85
Current Ratio
4.98
Debt
$733.00K
Total Assets
$369.64M
Current Assets
$68.15M
Working Capital
$114.19M

Ownership

Promoter Holding
17.65%
Chg in Prom Hold
-0.28%
FII / Inst Holding
45.12%
Chg in FII Hold
0.02%

Financial Snapshot

Enterprise Value
$203.81M
Total Revenue (TTM)
$0
EBITDA
$-14.40M
Free Cash Flow
$2.51M
Operating Cash Flow
$-5.21M
Shares Outstanding
40.93M
Gross Margin
0.00%
Payout Ratio
6.05%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ORMP Oramed Pharmaceuticals Inc. PHARMA 4.98 1.21 $203.81M 5.36% -7.12% 74.24% 13.48% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Feb 2015May 2015Nov 2015Feb 2016May 2016Nov 2016Feb 2017May 2017Nov 2017Feb 2018May 2018Nov 2018Feb 2019May 2019Nov 2019Feb 2020May 2020Nov 2020Feb 2021Mar 2021May 2021Jun 2021Sep 2021Nov 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue ---125.00K-163.00K610.00K611.00K617.00K611.00K604.00K617.00K674.00K666.00K682.00K674.00K674.00K681.00K674.00K665.00K666.00K681.00K674.00K682.00K674.00K666.00K674.00K682.00K666.00K674.00K-----2.00M0000-
Cost of Revenue ----------------------------------1.99M0000-
Gross Profit ----------------------------------13.00K0000-
Operating Expenses ----------------------------------4.51M2.49M2.43M5.67M3.66M-
Operating Income -1.67M-1.63M2.45M-1.91M2.11M-2.40M-3.37M-2.15M-2.73M-3.11M-4.53M-4.64M-3.57M-4.08M-2.43M-4.04M-2.27M-5.83M-4.87M-6.60M-6.12M-4.45M-7.49M-8.06M-11.25M-11.42M-8.19M-5.21M-3.79M-2.89M-2.96M-3.13M-3.09M--4.50M-2.49M-2.43M-5.67M-3.66M-2.77M
EBITDA -----------------------------------4.47M13.16M59.48M9.83M-3.63M-
Interest Expense ---------------------------------02.56M000--
Pretax Income -----------------------------------7.06M13.13M59.45M9.80M49.44M-
Tax Provision ----------------------------------584.00K-126.00K11.06M-212.00K11.13M-
Net Income -1.64M-1.58M-2.39M-1.82M2.00M-2.64M-3.18M-1.97M-2.53M-2.92M-4.35M-4.30M3.70M4.07M-2.54M-3.69M-2.28M-5.57M-4.61M-6.06M-5.21M-3.91M--8.10M-10.71M-10.53M-7.06M-3.40M-1.19M-3.22M1.54M9.21M-19.62M--7.64M13.29M48.40M10.01M38.31M78.16M
Diluted EPS ---------------------0.120.21-0.270.270.18-0.08-0.03-0.080.040.22-0.48--0.190.311.13-0.911.84
R&D Expense 1.14M915.00K-1.90M1.30M-1.71M2.35M3.12M2.27M2.33M2.72M4.19M4.35M3.11M3.86M2.02M3.32M1.93M5.77M3.87M6.17M5.50M3.20M6.09M6.41M5.84M9.18M5.35M4.43M1.82M957.00K1.18M1.44M2.24M-2.21M1.03M1.15M-1.59M-

Profit & Loss (Annual)

Figures in USD.

Metric Aug 2008Aug 2009Aug 2010Aug 2011Aug 2012Aug 2013Aug 2014Aug 2015Aug 2016Aug 2017Aug 2018Aug 2019Aug 2020Aug 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue --------641.00K2.46M2.45M2.70M2.71M2.70M2.70M1.34M02.00M
Cost of Revenue ----------------01.99M
Gross Profit ----------------013.00K
Operating Expenses --------------43.30M17.11M12.78M15.10M
Operating Income ----2.44M-2.88M4.30M-5.91M-7.38M-10.01M-10.77M-13.53M-14.63M-11.76M-24.22M-40.60M-15.77M-12.78M-15.09M
EBITDA ---------------37.61M7.32M-14.87M75.44M
Interest Expense --------------02.04M853.00K0
Pretax Income ---------------37.66M5.09M-15.92M75.32M
Tax Provision --------------100.00K03.18M11.31M
Net Income -2.77M-2.76M-2.98M-1.56M-3.34M4.23M-5.70M-7.23M-10.96M-10.48M-12.73M-14.36M-11.51M-22.99M-36.56M5.53M-19.06M64.05M
Diluted EPS ---------------0.940.14-0.481.50
R&D Expense ---1.16M1.68M-2.27M3.28M4.78M7.71M10.28M11.98M13.52M10.23M20.99M27.64M8.97M6.32M6.38M

Balance Sheet (Annual)

Figures in USD.

Metric Apr 2002Aug 2007Aug 2008Aug 2009Aug 2010Aug 2011Aug 2012Aug 2013Aug 2014Aug 2015Aug 2016Aug 2017Aug 2018Aug 2019Aug 2020Aug 2021Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -----4.33M5.29M8.66M21.80M26.35M42.83M38.71M47.40M34.66M44.63M-177.82M161.64M220.55M155.28M230.86M
Current Assets -----------------157.11M162.58M143.22M133.27M
Cash & Equivalents -----1.51M4.43M2.27M1.76M3.21M3.91M3.97M5.00M3.33M19.30M--40.46M9.05M54.42M45.95M
Inventory ---------------------
Receivables -------------------04.64M
Total Liabilities -----------------10.49M57.66M9.93M31.12M
Current Liabilities -----441.29K644.42K498.00K973.00K1.49M3.62M5.17M4.55M5.31M4.54M-7.37M5.75M53.21M5.68M19.09M
Long Term Debt ------------11.39M9.66M-------
Total Debt -----------------894.00K51.62M372.00K825.00K
Total Equity 53.70K513.13K4.59M2.75M830.27K3.72M3.78M8.13M20.79M24.83M26.19M19.24M31.11M19.39M32.88M-166.45M151.81M163.82M146.26M199.74M
Shares Outstanding -----------------39.56M40.34M39.92M39.28M

Cash Flows (Annual)

Figures in USD.

Metric Aug 2011Aug 2012Aug 2013Aug 2014Aug 2015Aug 2016Aug 2017Aug 2018Aug 2019Aug 2020Aug 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -1.71M-2.30M-3.40M-4.07M-4.95M4.66M-5.83M-14.66M-12.94M-12.44M--27.92M-10.29M-8.41M-9.14M
Investing Cash Flow -1.70M1.77M-4.57M-13.09M-3.31M-16.01M4.30M-7.00M11.26M4.63M-30.21M-73.04M105.82M5.44M
Financing Cash Flow 3.69M3.49M5.82M16.64M9.72M12.04M1.59M22.65M-23.79M-10.78M51.98M-52.04M-4.74M
Capital Expenditure -2.18K-2.00K-6.00K-14.00K-1.00K-9.00K-7.00K-5.00K-15.00K-82.00K--496.00K-254.00K-18.00K-1.93M
Free Cash Flow -1.71M-2.30M-3.40M-4.08M-4.95M4.65M-5.84M-14.66M-12.96M-12.52M--28.41M-10.55M-8.43M-11.08M
Net Change in Cash -----------13.07M-31.36M45.37M-8.44M
Share Buybacks -------------2.48M4.74M

Ratios (Annual)

Figures in %.

Metric Aug 2008Aug 2009Aug 2010Aug 2011Aug 2012Aug 2013Aug 2014Aug 2015Aug 2016Aug 2017Aug 2018Aug 2019Aug 2020Aug 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -----------------0.7%
Operating Margin % ---------1,561.6%-438.6%-552.3%-541.3%-433.8%-896.2%-1,502.0%-1,176.8%--754.4%
Net Margin % ---------1,710.5%-426.7%-519.7%-531.1%-424.8%-850.5%-1,352.6%412.3%-3,202.5%
ROE % -60.3%-100.5%-358.6%-41.9%-88.5%52.0%-27.4%-29.1%-41.9%-54.5%-40.9%-74.0%-35.0%--24.1%3.4%-13.0%32.1%
ROCE % ----62.7%-62.0%52.7%-28.4%-29.7%-25.5%-32.1%-31.6%-49.8%-29.3%--26.0%-9.4%-8.5%-7.1%

Shareholding Pattern

Insiders
17.65%
Institutions
45.12%
Public Float
54.80%

Top Institutional Holders

#Holder% HeldSharesValue
1 Mercer Global Advisors, Inc./ADV 9.16% 3.81M $18.06M
2 Aquamarine Financial (cayman) Ltd 6.04% 2.51M $11.91M
3 Gem Investment Advisors, LLC 4.81% 2.00M $9.47M
4 Blackrock Inc. 3.87% 1.61M $7.62M
5 Murchinson Ltd. 3.10% 1.29M $6.12M
6 BML Capital Management, LLC 2.08% 866.27K $4.11M
7 Boothbay Fund Management, LLC 1.39% 578.64K $2.74M
8 Geode Capital Management, LLC 1.20% 500.69K $2.37M
9 Goldman Sachs Group Inc 0.61% 253.29K $1.20M
10 State Street Corporation 0.58% 242.10K $1.15M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ORMP

Google News Wed, 17 Jun 2026

Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes - PR Newswire

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPNjZlb2hsYnJCTE03WUdqR1VwelhzWGtOb29vcUFIUmlfNzRWUUdBMGlIdnRtdEZBM3dkb20zaTg1MEhZc29EYVNmVE1mc2xoODkwS3pRVjh4X3FqLWFLYjkwMEFtTzNEWEcwNmRqUkVJWkl0bkxJZkF6MC11LVZiNDdpeEE0MWhWUnlCVH…

Google News hu, 03 Sep 2026

Oramed Pharmaceuticals Inc (NASDAQ: ORMP) Share Price, ORMP Stock News, ORMP Share Price & Updates - kalkine.com.au

<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE5Vd2pieGEzU2dUakdoNGN6WlJrOGQyalozcGdRcU9GMExVaEFwekhYZ1piOVNSY0J5Vk5nVk95azFfQnp4ZFJLT2pqTlhTQTM1ZUtUaXNn?oc=5" target="_blank">Oramed Pharmaceuticals Inc (NASDAQ: ORMP) Share Pri…

Google News Fri, 22 May 2026

Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxONmpPQmZvbGJpM1R4MTR6WHhUVVV0eHFLZjhkaW5oamlpWS1kZWZ1OFVjcTdiaW5iS0EtbTdhMHg2OU9jSlE1UUNOZXVuWFpmSWlRNW1kUEhFdlA0c1FZMDZXNy1Ec1J3bDFoLURQV3lUOHNjVng0RjNQZ3RsOURnRlprRGd4bTRhdXlZSH…

Google News hu, 28 May 2026

ORMP - Oramed Pharmaceuticals Inc Stock Price and Quote - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE16cDVpU1RydGZMWGdHdUJtX1FKQjBrOXVRUU1xVVA5U09XVmZxdlJaQkFwQzhfakRpYmFNQ3g2S08tQzZQY0E?oc=5" target="_blank">ORMP - Oramed Pharmaceuticals Inc Stock Price and Quote</a>&nbsp;&nbsp;<…

Google News hu, 25 Jun 2026

Oramed Pharmaceuticals Incorporated Actuals & Estimates (NASDAQ:ORMP) - tradingview.com

<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxOYXI4ZHlvZGhOeGo4MXlGOHgySzVmWUkxSFVTSXNITlAzbDdGdzE4R3VERGdydWdMTGpoLWRYRWlHY2xiRHVmcnJmRW16bWFWSFF5bWlHaUIyRUlSVE53b3RyNmVlcjVaRTlzaXJpdURhUGdCNXUtOHg3aXJHOEhCY3ZLRHBxZw?oc=5" t…

Google News Mon, 24 Nov 2025

ORMP: Advancing Clinical Activities, Generating Gains From Investment Portfolio, New Rights Plan Adopted - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxNN0JiTFczenRsc00zVWZEMkE2MS1hbXZQSFZydkZzOFdEanlEaS03Y19mTjhvaURVX3cwZ2ZCd19ySUtURkRhQ0Y3NmNsaFprWFZXOERNcy04ZjFKanZ2aUc3N21IUVdFUTJlX2Ywb01kWWtmWF9xTnNFSEI1VjZESldWR0RMQWQ2YzdOcG…

ORMP — Frequently Asked Questions

What is the current share price of Oramed Pharmaceuticals Inc. (ORMP)?

As of 2026-09-19 21:16 PDT, Oramed Pharmaceuticals Inc. (ORMP) trades at $4.98 on NasdaqCM. Its 52-week range is $1.92 to $5.34.

What is the market capitalisation of ORMP?

Oramed Pharmaceuticals Inc. (ORMP) has a market capitalisation of $203.81M on NasdaqCM.

What is the P/E ratio of ORMP?

ORMP trades at a trailing price-to-earnings (P/E) ratio of 1.21. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.62.

Does ORMP pay a dividend?

Oramed Pharmaceuticals Inc. (ORMP) currently offers a dividend yield of 5.36%.

What is the return on equity (ROE) of ORMP?

ORMP has a return on equity (ROE) of 74.24%. Its return on capital employed (ROCE) is -7.12%.

Is ORMP a good stock to buy?

This page provides a data-driven analysis of Oramed Pharmaceuticals Inc. (ORMP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space